Stocks · News reference
TD Cowen Maintains Buy on Halozyme Therapeutics, Raises Price Target to $105
TD Cowen analyst Brendan Smith maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the price target from $96 to $105.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 7, 2026, 9:05 PM
- Checked
- Aug 7, 2026, 9:05 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
8-K filing — HALOZYME THERAPEUTICS, INC. (HALO)
Filed: 2026-08-18 AccNo: 0001159036-26-000106 Size: 170 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Read original at edgarWatching Halozyme Therapeutics; Hearing Investor Business Daily SwingTrader Buys Stock
Read original at benzingaTop 3 Health Care Stocks That May Implode In August
3 health care stocks with high momentum could be overbought. Crinetics Pharmaceuticals (CRNX) has RSI of 90.6, Alamar Biosciences (ALMR) at 86.8, and Halozyme Therapeutics (HALO) at 81.7.
Read original at benzinga